Novartis ADR saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 68 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating north of 80 as they begin their biggest runs. See if Novartis ADR can continue to show renewed price strength and clear that threshold.
Novartis ADR is in a buy range after climbing above a 116.91 buy point in a consolidation. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to hold off investing and wait for it to set up another buying opportunity..
The company showed 27% EPS growth last quarter, while sales growth came in at 12%.
Novartis ADR holds the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
